(DERM) - Earnings & Price History

DERM: - 26.9, $1.12B, 0.13 (0.49%)

Sector: Healthcare - Industry: Biotechnology

Dermira, Inc., a biopharmaceutical company, engages in identifying, developing, and commercializing therapies to enhance the lives of patients with dermatologic diseases primarily in the United States. The companys late-stage product candidates comprise Cimzia, an injectable biologic tumor necrosis factor-alpha inhibitor, which is in Phase III clinical trial for the treatment of moderate-to-severe chronic plaque psoriasis; DRM04, a small-molecule anticholinergic product that is in Phase III clinical trial for the treatment of primary axillary hyperhidrosis or excessive underarm sweating; and DRM01, a small-molecule sebum inhibitor, which is in Phase IIb clinical trial for the treatment of acne vulgaris. Dermira, Inc. has a collaboration agreement with UCB Pharma S.A. for the development and commercialization of Cimzia. The company was formerly known as Skintelligence, Inc. and changed it

Past DERM reports
Earning DateTimeTitleEPS-e EPS-a ClosePrev CloseOpen Day LowDay High Gap % CFO %Change % Volume
2017-02-28AMC-0.834.3233.6934.2832.0736.681.75%0.12%1.87%682.11K
2016-05-10BMO-0.9428.6924.462926.5229.4418.56%-1.07%17.29%1.45M
2016-03-03BMO-0.9521.823.2622.9321.4223.15-1.42%-4.93%-6.28%215.88K
2015-11-10-0.7728.2628.127.6627.1428.77-1.57%▲2.17%0.57%139.29K
2015-03-25AMC-0.615.9314.6515.6515.2516.26.83%1.79%8.74%70.19K

Login | Register
Saturday Nov 17, 2018   EST
Enter a Ticker:

Economic Calendar

AAII Sentiment Survey

BULL^ neut ^ BEAR

Chart

index chart
index color
SPY257.6450.500.19%41,867,194

Upgrades/Downgrades